
Opinion|Videos|May 7, 2024
Evaluating the Impact of Metastatic Breast Cancer on Patients
An expert panel discusses the clinical and economic impact of metastatic breast cancer (mBC) on patients, the prognosis for those with mBC, the three FDA-approved CDK4/6 inhibitors for HR+/HER2- mBC, and the importance of overall survival as a clinical trial endpoint and its relevance to clinical practice.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Early Recognition and Routine Discussion: Improving Outcomes in Tardive Dyskinesia
2
Do GLP-1 Receptor Agonists Increase the Risk of Smell and Taste Disturbances?
3
Melatonin May Reduce Musculoskeletal Pain and Improve Sleep
4
White Bagging, Brown Bagging, and the Pharmacist Caught in the Middle
5











































































































